🔖
Cite This Article
BARIŞ, V. Ö., ERDEM, A. (2022). Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 4, 342–343. https://ajindex.com/articles/407422
Journals / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 4
Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
- Pages
- 342–343
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (6)
- Dindaş F, Güngör H, Ekici M, et al. Angiotensin receptor- neprilysin inhibition by sacubitril/valsartan attenuates doxoru- bicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and caspase 3 apoptotic pathway. Anatol J Cardiol. 2021
- 25(11):821-828. [CrossRef] 2. Barış VÖ, Gedikli E, Yersal N, Müftüoğlu S, Erdem A. Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings. Amino Acids. 2019
- 51(10-12):1649-1655. [CrossRef] 3. Muindi JR, Sinha BK, Gianni L, Myers CE. Hydroxyl radical pro- duction and DNA damage induced by anthracycline-iron com- plex. FEBS Lett. 1984
- 172(2):226-230. [CrossRef] 4. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molec- ular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012
- 18(11):1639-1642. [CrossRef] 5. Cowgill JA, Francis SA, Sawyer DB. Anthracycline and peripartum cardiomyopathies. Circ Res. 2019
- 124(11):1633-1646. [CrossRef